AU593383B2 - Creation of Inventions and Patents with Artificial Intelligence

AU593383B2 – Spiro derivatives
– Google Patents

AU593383B2 – Spiro derivatives
– Google Patents
Spiro derivatives

Download PDF
Info

Publication number
AU593383B2

AU593383B2
AU78278/87A
AU7827887A
AU593383B2
AU 593383 B2
AU593383 B2
AU 593383B2
AU 78278/87 A
AU78278/87 A
AU 78278/87A
AU 7827887 A
AU7827887 A
AU 7827887A
AU 593383 B2
AU593383 B2
AU 593383B2
Authority
AU
Australia
Prior art keywords
alkyl
groups
halogens
carbamoyl
phenyl
Prior art date
1986-09-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Application number
AU78278/87A
Other versions

AU7827887A
(en

Inventor
Goro Asato
Donald John France
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Wyeth Holdings LLC

Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1986-09-12
Filing date
1987-09-11
Publication date
1990-02-08

1987-09-11
Application filed by American Cyanamid Co
filed
Critical
American Cyanamid Co

1988-03-17
Publication of AU7827887A
publication
Critical
patent/AU7827887A/en

1990-02-08
Application granted
granted
Critical

1990-02-08
Publication of AU593383B2
publication
Critical
patent/AU593383B2/en

2007-09-11
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07D—HETEROCYCLIC COMPOUNDS

C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system

C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS

C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof

C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen

A—HUMAN NECESSITIES

A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING

A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS

A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds

A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system

A—HUMAN NECESSITIES

A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING

A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS

A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid

A01N47/08—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having one or more single bonds to nitrogen atoms

A01N47/10—Carbamic acid derivatives, i.e. containing the group —O—CO—N<; Thio analogues thereof A01N47/24—Carbamic acid derivatives, i.e. containing the group —O—CO—N<; Thio analogues thereof containing the groups, or; Thio analogues thereof A—HUMAN NECESSITIES A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid A01N47/08—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having one or more single bonds to nitrogen atoms A01N47/28—Ureas or thioureas containing the groups >N—CO—N< or >N—CS—N< A01N47/34—Ureas or thioureas containing the groups >N—CO—N< or >N—CS—N< containing the groups, e.g. biuret; Thio analogues thereof; Urea-aldehyde condensation products A—HUMAN NECESSITIES A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES A23K—FODDER A23K20/00—Accessory food factors for animal feeding-stuffs A23K20/10—Organic substances A23K20/195—Antibiotics A—HUMAN NECESSITIES A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS A61P33/00—Antiparasitic agents A61P33/10—Anthelmintics Description i)i i r ri i S F Ref: 36990 FORM COMMONWEALTH OF AUSTRALIA -it ,rtsdenuetl and I corrf for prw*; PATENTS ACT 1952 COMPLETE SPECIFICATION F 9 33 (ORIGINAL) 9 3 FOR OFFICE USE: Class Int Class Complete Specification Lodged: Accepted: Published: Priority: Related Art: I,* 4 I Name and Address of Applicant: Address for Service: American Cyanamid Company One Cyanamid Plaza Wayne New Jersey UNITED STATES OF AMERICA Spruson Ferguson, Patent Attorneys Level 33 St Martins Tower, 31 Market Street Sydney, New South Wales, 2000, Australia .r t t Complete Specification for the invention entitled: 1 3-deoxy-23-oxor(kto) and 23-iminn Darivatives of 13-drexy C- 76-agly~nio C~mpeunds--- 2Ptlko De.dkv Arives The following statement is a full description beet method of performing it known to me/us of this invention, including the I ii'l E 5845/3 c -I- 30,398-00 *j 4 *P I 4r t t I! 4I 4r I, I 4 4 I I I OERv-TweS- 3PEOXYV-33-OXO (YXI'0) AND 23 fMINE--- DERIVATIVES'OF 13-DEOXY C-076-AGLYCONE COMrPOUNDZ ABSTRACT OF THE INVENTION The _resent invention relates to novel 23-oxo (keto) and 23-imino derivatives of C-076 wherein the C-076 compounds are not substituted at the 13-position. The C-076 compounds (collectively) are isolates from the fermentation broth of Streptomyces avermitilis. The present 23-oxo compounds are prepared by selectively iO oxidizing suitably protected 13-deoxy C-076 aglycone compounds by using oxidizing agents. Subsequently, the 23-oxo compounds are converted to the 23-imino compounds. These novel compounds have potent anthelmintic, insecticidal, ectoparasiticidal, nematicidal and acaricidal activity. Compositions containing these 23-oxo and 23-imino derivatives of 13-deoxy C-076 aglycones also are described herei..t Sii i I ;-j 30,398-00 13-DEOXY-23-OXO (KETO) AND 23-IMINO DERIVATIVES OF 13-DEOXY C-076-AGLYCONE COMPOUNDS BACKGROUND OF THE INVENTION The _resent invention relates to new 23-oxo (keto) and 23-imino derivatives of the compounds collectively defined as 13-deoxy-C-076 aglycones. The C-076 .o antibiotics preferably are produced by the fermentation of the microorganism Streptomyces avermitilis with the S" 10 13-deoxy-C-076 aglycone compounds having been disclosed. 0« The C-076 compounds are complex macrolides which have a 23-hydroxy substituent. The selective oxidation of this 23-hydroxy group to a 23-oxo group and the subsequent derivatization of the oxo group to afford 15 23-imino derivatives are the subject matter of the present invention. These 23-oxo and 23-imino derivatives *of the 13-deoxy-C-076 aglycone compounds are useful for the prevention- treatment or control of helmintic, ectoparasitic, insect, acarid and nematode infections and S 20 infestations in warm-blooded animals and agricultural I I crops. I -2- SUMMARY OF THE INVENTION The present invention provides novel 23-oxo (keto) and 23-imino derivatives of the compounds designated 13-deoxy-C-076 aglycones. The 13-deoxy-C-076 aglycone compounds have the following structural formula: CH 0\ 2H 3 3 1R wherein the broken line indicates a single or a double bond; R is halogen or hydrogen; R 1 is hydroxy and is Tpresent only when said broken line indicates a single bond; R 2 is isopropyl or sec-butyl; and R 3 is methoxy or hydroxy. The compounds of the present invention are useful anthelmintics, ectoparasiticides, insecticides, acaricides and ematicides in treating, preventing or controlling such diseases in warm-blooded animals, such as poultry, cattle, sheep, swine, rabbits, horses, dogs, cats and human beings. -3- Although these diseases have been recognized for years and therapies exist for the treatment and prevention of the diseases, the present invention provides novel compounds in the search for effective such therapy. U.S. Patent 3,950,360, Aoki et al, April 13, 1976 discloses certain antibiotic substances obtained by culturing a Streptomyces microorganism, said compounds being useful as insecticides and acaricides. Further, an entire series of U.S. patents relates to certain comtApril 22, 1980; U.S. Patent 4,206,205, Mrozik et al, June 3, 1980; U.S. Patent 4,310,519, Albers-Schonberg, January 12, 1982; U.S. Patent 4,333,925, Buhs et al, June 8, 1982). U.S. Patent 4,423,209, Mrozik, December 27, 1983 relates to the process of converting some of these less desirable components to more preferred ones. Finally, British Patent Application No. 2166436 A discloses antibiotics also. European Patent Application Publication No. 170,006 also discloses useful such antibiotics. The present compounds or the pharmaceutically S 25 and pharmacologically acceptable salts thereof exhibit excellent and -effective treatment, prevention and/or e control of these serious diseases of warm-blooded animals. -4- It is an object of the present invention, therefore, to provide novel 23-oxo and 23-imino derivatives of 13-deoxy-C-076 aglycone compounds. It is a further object to provide a process for the preparation of these derivatives and to provide methods for preventing, treating or controlling endo and ectoparasitic (collectively parasitic), insect, nematode, acarid and helmintic diseases and infestations in warm-blooded animals and agricultural crops by providing compositions containing prophylactically, therapeutically or pharmaceutically-effective amounts of the present novel compounds. These and other objects of the invention will become apparent±by: the more detailed description of the 15 invention provided hereinbelow. i i S* 3 t (t 3 I _r .i DETAILED DESCRIPTION OF THE INVENTION The 13-deoxy-C-076.. aglycone compounds which Smay act as precursors of the present compounds are represented by the following structural formula, 2 t V CH '3 3 1 I 0 CR I 3 R3 i Swherein the broken line indicates a single or a double bond; R is halogen or hydrogen; R 1 is hydroxy and is present only when said broken line indicates a single bond; R 2 is isopropyl or sec-butyl; and R 3 is methoxy or hydroxy. j The compounds of the instant invention are Si represented by the following structural formula: HI 25 F /33 S 5 11 K\ S* 2 sec-butyl; X is oxygen, NOR or N-NHR R is hydrogen, ,fC' (1) wherein R 1 is methoxy or hydroxy; R 2 is isopropyl or sec-butyl; X is oxygen, NOR 4 or N-NHR 5 R 4 is hydrogen, i i i _C *1 -6- C1-C 6 alkyl, C1-C 4 alkoxymethyl, benzoyl, allyl, propargyl, phenyl, CH 2 COO-alkyl (C 1 C 4 N-(C 1 -C 6 alkyl)carbamoyl, N-(allyl)carbamoyl, N-(propargyl)carbamoyl, N-(phenyl)carbamoyl, N-(chlorophenyl)carbamoyl, N-(dichlorophenyl)carbamoyl, N-(benzyl)carbamoyl, C1-C 6 alkaxoyl, chloroacetyl, methoxyacetyl, phenylacetyl, optionally substituted on the phenyl ring with one or two halogens, C -C 4 alkyl groups, C--C 4 alkoxy groups or nitro groups, phenoxyacetyl, optionally substituted on the phenyl ring by one or two halogens, C 1 -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups, or benzoyl, optionally substituted with one or two halogens, C 1 -C 4 alkyl groups, C -C 4 alkoxy groups or nitro groups; R 5 is -NRg 6 R, C-OR 8 NR R R, C-C alkanoyl, 15 6 7, 6 V' 7' 1' formyl, C 1 -C 6 alkyl, -NR R6, benzoyl, optionally substituted with one or two halogens, C-Cq alkyl groups, C1-C 4 alkoxy groups or nitro groups; R 6 and R are hydrogen or C 1 -C 6 alkyl; or phenyl, optionally substituted with one or two halogens, C -C 4 alkyl, C 1 -C 4 alkoxy, or phenyl optionally substituted with one or two halo- S t gens, C 1 -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups, R 8 is C 1 -C 6 alkyl or phenyl optionally substitu- 25 ted with one or two halogens, C 1 -C 4 alkyl groups, C1-C 4 alkoxy groups or nitro groups; R 9 is C 1 -C 6 alkyl or phenyl optionally substituted with one or two halogens, C 1 -C 4 alkyl groups, C -C 4 alkoxy groups or nitro groups; and the pharmaceutically and pharmacologically acceptable salts thereof. r a1 -7- A preferred group of compounds of structure includes R1as hydroxy; R 2 as isopropyl or sec-butyl; X as oxygen, NOR 4 INH-I~NR 6 R 7 NMM- OR., or NNHCH 3 arnd R 4 R 6 R 7 and R as described hereinabove. Another preferred group of compounds of structure includes R1as hydroxy; R 2 as isopropyl or sec-butyl; X as oxygen, NOR 4 NNH-9-NR 6 R 7 or NNH-CH 3 R 4 as C 1 -C 3 alkyl, N-(C 1 -C 4 alkyl)carbamoyl, N-(phenyl)carbamoyl, N- (allyl) carbamoyl, N- (4-chlorophenyl) carbamoyl, N-(benzyl)carbamoyl, C 1-C4 alkanoyl, chioroacetyl, methoxyacetyl, phenioxyacetyl, benzoyl and chioroberizoyl; ~15 and R 6 and R. 7 as described hereinabove. The most preferred group of compounds of 4.stru-.ture includes R as hdoy siorplo secbutl;X as NOR 4 NNH-9-NR R 7 or NNHR R 6 andR 2 0 as hydrogen or C 1 -C 4 alkyl; and R 5 as C 1 -C 4 alkyl or C 1 -C 4 alkanoyl. In preparing the compounds of the present invention, the 5-hydroxyl group must be protected. A Suitable protecting groups are trisubstituted silyl 25 groups, such as t-butyldimethylsilyl and trimethylsilyl, or trisubstituted silyloxyacetyl groups, such as t-butyldimethylsilyloxyacetyl group. The protecting groups, however, are not limited to these groups since other 4 0 0 0 useful protecting groups such as acyl and substituted acyl, such as acetyl, trifluoroacetyl, chioroacetyl, trichloroacetyl, phenoxyacetyl and the like, are also useful in the present process. I I i ~wuw~~urr*r*uw~,. -8- One of the preferred protecting groups is f-butyldimethylsilyl. This group is attached to the group by reacting an unprotected F-28249 compound with t-butyldimethylsilyl chloride in the presence of a base, such as imidazole, pyridine, 4-dimethylaminopyridine, triethylamine and the like, in an aprotic solvent such as methylene chloride, toluene, ethylacetate, tetrahydrofuran, ethylenedichloride and the like. The reaction is stirred at a temperature of about 0°C to 30°C, and the reaction is complete in several hours, depending on the temperature of the reaction. The completion of the reaction is usually monitored by high it performance liquid chromatography (HPLC) using reverse phase on a Whatman Partisil CCS/C 8 rapid analysis column. Another preferred protecting group is t-butyldimethylsilyloxy acetyl group. This group is attached to the 5-hydroxyl group by combining the unprotected F-28249 compound in an aprotic solvent such as methylene chloride, toluene, ethyl acetate, tetrahydrofuran, ethylenedichloride and the like, containing a tertiary amine, such as pyridine or triethylamine, and adding the protecting agent in the form of an acid halide. The reaction is'conducted at a temperature of about 0 0 C to 30 0 C t and is monitored by HPLC for completion. The 23-hydroxyl group of the protected 13deoxy-C-076-aglycone compound then is oxidized to the t 23-oxo (or keto) group by using oxidizing agents such as pyridinium dichromate, pyridinium chlorochromate, chromic acid-dimethylpyrazole, acetic anhydride/dimethylsulfoxide, trifluoroacetic anhydride/dimethylsulfoxide, N- -9chlorosuccinimide/dimethylsulfoxide, oxalyl chloride/dimethylsulfoxide and the like. The reaction is carried out at dry-ice bath temperatures (about -780C) to room temperature (about 250C) and is complete in about 1 to 24 hours, depending on the rate of oxidation, which is monitored by HPLC. The dimethylsulfoxide oxidation procedures are carried out in the presence of a tertiary amine such as triethylamine or diisopropylethylamine. i Solvents such as methylene chloride, ethylenedichloride, dimethylformamide, dimethylsulfoxide and the like are used. In using oxalyl chloride/dimethylsulfoxide in the presence of triethylamine, it is advantageous to add molecular sieves to the reaction mixture to increase the Syield. The oxidation may also be carried out by soil microorganisms using 100 mg to 10 g of a 23-hydroxy compound per liter of unsterilized soil at 20°C to 30 0 C. The oxidized 23-keto compound is extracted from the soil by a solvent such as acetone, methanol or ethanol. The silyl protecting group is removed by stirring a protected 23-deoxy-C-076 compound in a lower alkanol such as methanol at 00 to room temperature for about 0.5 hour to an hour in the presence of an acid such S' as P-toluenesulfonic acid. If the protecting group is a silyloxyacetyl group, the silyl group is removed with S 25 acid as described above, and the hydroxyacetyl group is cleaved with an equivalent of base such as sodium methoxide in methanol at 00 to room temperature in 0.5 hour to several hours. The silyloxyacetyl group may also be removed in one step by treatment with sodium methoxide at room temperature until the reaction is complete. Similarly, other acyl protecting groups are removed by base treatment. The imino derivatives of the 23-oxo compounds are readily prepared by standard techniques such as procedures described by S. M. McElvain in The Characterization of Organic Compounds, published by MacMillan Company, New York, 1953, pages 204-205. Typically, a 23-oxo compound is stirred in alcohol, such as methanol or'-ethanol, or dioxane in the presence of acetic acid and an excess of the amino derivatizing agent, such as hydroxylamine hydrochloride, 0-methylhydroxylamine hydrochloride, semicarbazide hydrochloride and the like along with an equivalent amount of sodium acetate, at room temperature to 50 0 C. The reaction is usually complete in several hours to several days at room temperature but can be readily speeded by heating. The 0-acyloximes or carbamoylated oximes are prepared by treating the oximes of structure with acid anhydride sor isocyanates to afford wherein R is C 1 -C 6 alkanoyl, chloroacetyl, methoxyacetyl, phenylacetyl, benzoyl, chlorobenzoyl, N-(C 1 -C 4 alkyl)carbamoyl, N-(allyl)carbamoyl, N-(propargyl)-carbamoyl, N-(phenyl)carbamoyl, N-(chlorophenyl)carbamoyl, N-dichlorophenyl)carbamoyl or N-benzyl)carbamoyl. The reactions are conducted in inert solvents, such as methylene chloride, ethylenedichloride or dioxane, in the presence of a tertiary amine, such as triethylamine or diisopropylr ethylamine. Generally, the reactions are conducted from 0 C to room temperature, but if the reactions are sluggish, heat is applied. An equivalent to a slight excess I 25 of the acid anhydride is used to avoid reaction at the group.- The novel compounds of the present invention have significant activity as anthelmintics, ectoparasiticides, insecticides, nematicides and acaricides in human and animal health areas and in agriculture. The disease or group of diseases described generally as helminthiasis is due to infection of an animal host with parasitic worms known as helminths. Helminthiasis is a prevalent and serious economic problem in domesticated animals such as swine, sheep, horses, cattle, goats, dogs, cats and poultry. Among the -11helminths, the group of worms described as nematodes causes widespread and often times serious infection in various species of animals. The most common genera of nematodes infecting the animals referred to above are Haemonchus, Trichostrongylas, Ostertagia, Nematodirus, Cooperia, Ascaris, Bunostomum, Oestophagostomum, Chabertia, Trichuris, Strongylus, Trichonema, Dictyocaulus, Capillaria, Heterakis, Toxocara, Ascaridia, Oxyuris, Ancylostoma, Uncinaria, Toxascaris and Paracaris. Certian of these, such as Nematodirus, Cooperia, and Oesphagostomum primarily attack the intestinal tract while others, such as Haemonchus and Ostertagia, are most prevalent in the stomach. Still others such as Dictyocaulus are found in the lungs. Also, other parasites may be located in other tissues and organs of the body such a- the heart and blood vessels, subcutaneous and lymphatic tissue and the like. The parasitic infections known as helminthiases lead to anemia, malnutrition, weakness, weight loss, severe damage to the walls 20 of the intestinal tract and other tissues and organs, and if left untreated, may result in death of the infected host. The 23-oxo or -imino derivatives of 13-deoxy-C-076 r aglycone compounds of this invention unexpectedly have high activity against these parasites. Additionally, 25 they also are active against Dirofilaria in dogs, Nematospiroides, Syphacia, Aspiculuris in rodents, arthropod ectoparasites such as ticks, mites, lice, fleas, blowfly of animals and birds, the ectoparasite Lucilia sp. of i i' sheep, biting insects and migrating dipterous larvae such as Hypoderma sp. in cattle, Gastrophilus in horses and Cuterebra sp. in rodents. The compounds of the present invention also are useful in treating, preventing or controlling parasites which infect human beings, as well. The most common genera of parasites of the gastrointestinal tract of man are Ancylostoma, Necator, Ascaris, Strongyloides, Trichinella, Capillaria, Trichuris, and Enterobius. Other I li i I L;11:_.li: ::~_~LIIIIICII i~ ll~ -12medically important genera of parasites which are found in the blood or other tissues and organs outside the gastrointestinal tract are the filiarial worms such as Wuchereria, Brugia, Onchocerca and Loa, Dracunculus and extra-intestinal stages of the intestinal worms Strongyloides and Trichinella. The present compounds also are of value against arthropods parasitizing man, biting insects and other dipterous pests causing annoyance to man. These compounds further are active against household pests such as the cockroach, Blattella sp., clothes moth, Tineola sp., carpet beetle, Attagenus sp., and the housefly- Musca domestica. Insect pests of stored grains such as Tribolium 15 sp., Tenebrio sp., and of agricultural plants such as It spider mites (Tetranycus southern army worms, tobacco budworms, boll weevils, aphids (Acyrthiosiphon migratory orthopterans such as locusts and immature 1* stages of insects living on plant tissue are controlled 20 by the present compounds as well as the control of soil nematodes and plant parasites such as Meloidogyne sp., which may be of importance in agriculture. The compounds of the present invention may be 4 administered orally or parenterally for animal and human usage, while they may be formulated in liquid or solid form for agricultural use. Oral administration may take the form of a unit dosage form such as a capsule, bolus or tablet, or as a liquid drench where used as an anthelmintic for animals. The animal drench is normally a solution, suspension or dispersion of the active compound, usually in water, together with a suspending agent such as bentonite and a wetting agent or like excipient. Generally, the drenches also contain an antifoaming agent. Drench formulations generally contain about 0.001% to by weight, of the active compound. Preferred drench formulations contain about 0.01% to 0.1% by dl~ .i; -13t ft tr A (A Iit weight. Capsules and boluses comprise the active ingredient admixed with a carrier vehicle such as starch, talc, magnesium stearate or di-calcium phosphate. Where it is desired to administer the 23-oxo or 23-imino derivatives of 13-deoxy-C-076 aglycone in a dry, solid unit dosage form, capsules, boluses or tablets containing the desired amount of active compound usually are employed. These dosage forms are prepared by intimately and uniformly mixing the active ingredient with suitable finely divided diluents, fillers, disintegrating agents and/or binders such as starch, lactose, talc, magnesium stearate, vegetable gums and the like. Such unit dosage formulations may be varied widely with respect to their total weight and content of the active compound depending upon factors such as the type of host animal to be treated, the severity and type of infection and the weight of the host. When the active compound is to be administered via an animal feedstuff, it is intimately dispersed in the feed or used as a top dressing or in the form of pellets which may then be added to the finished feed or optionally fed separately. Alternatively, the active compounds of the present invention may be administered to 25 animals parenterally, such as by intraruminal, intramuscular, intratracheal, or subcutaneous injection. In such an event, the active compound is dissolved or dispersed in a liquid carrier vehicle. For parenteral administration, the active compound is suitable admixed with an acceptable vehicle, preferably of the vegetable oil variety such as peanut oil, cotton seed oil and the like. Other parenteral vehicles such as organic preparations using solketal, propylene glycol, glycerol formal, and aqueous parenteral formulation also are used. The active 23-oxo or -imino compound or compounds of the present invention are dissolved or suspended in the parenteral formulation for IAI AA A A AtA SA' >1 1′ -14administration. Such formulations generally contain about 0.005% to by weight, .of the active compound.
Although the compounds of the present invention are primarily uses in the treatment, prevention or control of helminthiasis, they also are useful in the prevention and treatment of diseases caused by other parasites. For example, arthropod parasites such as ticks, lice, fleas, mites and other biting insects in domesticated animals and poultry are controlled by the present compounds. These compounds also are effective in treatment of parasitic diseases that occur in other animals including human beings. The optimum amount to be employed will, of course, depend upon the particular compound employed, the species ofanimal to be treated and 15 the type and severity of parasitic infection or infestation. Generally, the amount useful in oral administration of these novel compounds is about 0.001 mg to 10 mg per kg of animal body weight, such total dose being given at one time or in divided doses over a relativelyshort period of time (1-5 days). The preferred compounds of the invention give excellent control of such parasites in animals by administering about 0.025 mg to 3 mg per kg of animal body weight in a single dose. Repeat treatments ,t *are given as required to combat re-infections and are j o, 25 dependent upon the species of parasite and the husbandry I techniques being .employed. The techniques for administering these materials to animals are known to those skilled in the veterinary field.
When the compounds described herein are administered as a component of the animal’s feed, or dissolved or suspended in the drinking water, compositions are 1 provided in which the active compound or compounds are intimately dispersed in an inert carrier or diluent. An inert carrier is one that will not react with the active component and that will be administered safely to animals. Preferably, a carrier for feed administration is one that is, or may be, an ingredient of the animal ration.
Suitable compositions include feed premixes or supplements in which the active compound is present in relatively large amounts, wherein said feed premixes or supplements are suitable for direct feeding to the animal or for addition to the feed either directly or after an intermediate dilution or blending step.
Typical carriers or diluents suitable for such compositions include distillers’ dried grains, corn meal, citrus meal, fermentation residues, ground oyster shells, wheat shorts, molasses solubles, corn cob meal, edible bean mill feed, soya grints, crushed limestone and the like. The active_ compounds are intimately dispersed throughout the carrier by methods such as grinding, 8stirring, milling or tumbling. Compositions containing about 0.005% to by weight, of the active compound are par:ticularly suitable as feed premixes.
Feed supplements, which are fed directly to the animal, contain about 0.0002% to by weight, of the %ti 20 active compounds. Such supplements are added to the feed in an amount to give the finished feed the *1 concentration of active compound desired for the treatment, prevention and/or control of parasitic diseases.
Although the desired concentration of active compound will vary depending upon the factors previously mentioned K 8 4’25 as well as upon the particular derivative employed, the compounds of this invention are usually fed at concentrations of about 0.00001% to 0.02% in the feed in order to achieve the desired antiparasitic result.
The compounds also may be administered by pouring on the skin of animals via a solution. Generally, the actilve compounds are dissolved in a suitable inert solvent, such as dimethylsulfoxide, propylene glycol of the like, alternatively in combination of solvents, for the pour-on administration.
The compounds of this invention also are useful in combating agricultural pests that inflict damage upon r -16growing or stored crops. The present compo.nds are applied, using known techniques such as sprays, dusts, emulsions and the like, to the growing or stored crops to effect protection from such agricultural pests.
The present invention is illustrated by the following examples which are illustrative of said invention and not limitative thereof.
EXAMPLES 1-3 13-Deoxy-23-oxo-C-076-B2a-aglycone A solution containing 0.32 g of oxalyl chloride in 5 mL of CH 2 C1 2 is cooled and stirred with 0.71 g of Type 4A molecular sieves in a dry-ice/acetone bath. A mixture of 0.4 g-of dimethylsulfoxide (DMSO) in 2 mL of j 15 CH 2 C12 is added slowly with stirring under N 2 atmosphere.
Subsequently, 0.83 g of 5-0-t-butyldimethylsilyl-13deoxy-C-076-B2a-aglycone in 8 mL of CH 2 C12 is added dropwise over iC minutes. After 0.5 hours, 1.6 mL of triethylamine is added dropwise, and the mixture’s 20 temperature is allowed to rise to room temperature over an hour. The mixture is poured on ice-H20 mixture, and the aqueous mixture is extracted with 3 x 10 mL of Et 2 0.
The Et20 layers are washed with H 2 0 (5 x 5 mL) and dried S” (M 9 S0 4 Ether is removed, and the residue is dissolved in 15 mL of MeOH. The MeOH solution is stirred at 0°C with 0.3 g of E2toluenesulfonic acid for 3 hours and poured into 60 mL of saturated NaHCO 3 and 60 mL of H 2 0.
The aqueous mixture is stirred with NaCl until it is saturated and extracted with EtOAc (3 x 40 mL). The combined EtOAc layers are dried (M SO and evaporated to dryness to afford the title compound that is identified j by mass spectrometry and NMR spectroscopy.
Similarly 5-0-t-butyldimathylsilyl-13-deoxy- 23-oxo-C-076-B2b-aglycone is obtained from its corresponding alcohol. It is desilylated. Also, the oxidation of 5-0-t-butyldimethylsilyl-13-chloro-13-deoxy- C-076-B2a-aglycone affords 13-chloro-13-deoxy-23-oxo- -17..
C-076-B2a-aglycone.
4. 9 4 @4 14 4 i~9 4* 40 4 49 4 44 4. o a, .4 ft.
ft
CC
ffSgtg 0 4 I S~III
I
13-Deoxv-23-oxo-C-076-A2a-aclycone Using the procedure of Examples 1 to 3, butyldimethylsilyl-13-deoxy C-076-A2a-aglycone is oxidized to give the title compound that is identified by mass spectrometry and NMR spectroscopy.
10 EXAMPLE 13-Deoxv-23-0-Methvloxime-C-076-B2a-aglycone In 9 mL of dry dioxane at room temperature, 0.70 g of 23-oxo-C-076-B2a-aglycone, 0.12 g of NaQAc, 0.12 g of CH 3ONH 2%HC1 and 0.02 mL of HOAc are added. The 15 mixture is stirred under N 2 for 3 days, and after no starting material is detected by HPLC, dioxane is evaporated in vacuo. The residue is poured into 50 mL of H 2 0of and the product is extracted with CH 2 C.2 (4 x 20 mL).
The combined extracts are washed with H 2 0, dried (Na 2 so 4 and evaporated to dryness. The residue is dissolved in 15 mL of Et 2 0, and the solution is washed with H 2 0, dried (Na 2 so 4 and evaporated to dryness to give the title compound that is identified by mass spectrometry and NIIR spectroscopy.
EXAMPLE 6 13-Deoxyv-23-oxime-C-076-B2a-aglvcone In 5 mL of dioxane, 62 mg of 13-deoxy-23-oxo- C-076-B2a-aglycone is stirred with 49 mg of NH 2 OHvHCl, 58 mg of NaOAc and 10 jil of HOAc for 23 hours under N 2 atmosphere. The mixture is poured into 250 mL each of H 20 and CH 2Cl 2, and the CH 2 C1 2 layer is separated. The aqueous layer is extracted with 50 mL of CH 2 C1 2 2 and the combined CH 2 Cl 2 solutions are washed with H2 0, dried (Na 2 so 4 and evaporated to dryness to afford 8.8 mg of residue. This material is purified on a preparative layer plate (silica, gel) using 20% MeCH in CH-I 2 Cl 2 to
I
-18afford the title compound that is identified by mass spectrometry and NMR spectroscopy.
EXAMPLE 7 13-Deoxv-23- ro- (methvlcarbamovl)oximel-C-076-B2a-aqlvcone In 5 mL of Et 2 0 27.2 mg of 13-deoxy-23-oxo- C-076-B2a-aglycone is stirred under N 2 with 10 pl of Et3N and 50 pL of methyl isocyanate for 17 hours at room temperature. The ether is evaporated, and the residue is 10 purified on a preparative chromatography plate (silica gel) using 20% MeOH in CH2C1 2 to afford the title comr pound that is identified by mass spectrometry and NMR spectroscopy.
15 EXAMPLES 8-17 Using the method of Example 4, the following 13-deoxy-23-0-substituted oxime-C-076-B2-aglycone compounds are prepared using the appropriate O-substituted hydroxylamines in place of methoxyamine.
CH3 II
S
2 5 \cN3
R
(1) 7 -19- #9 4 9 0 #4 9 490 *9 *9 4 9.4 4. 4 4. ft 996 0 10
OH
OCH 3
OH
OH
OH
OH
OH
OH
OH
OCH 3 sec-buty.
isopropyl sec-butyl sec-butyl sec-butyl sec-butyl sec-butyl sec-butyl sec-butyl -sec-butyl
X
N-O-ethyl N-O-ethy.
N-O- isopropyl N-O-ri-hexyl N-O-benzyl N-O-allyl N-O-propargyl N-O-CH 2COOC N-OCH 2COOC 4H9 N-O-ethyl EXAMPLES 18-27 Using the method of Example 7, the following 23- (0-substituted-carbamnoyl) oximes are prepared: FT3* i/ 3 r C4 t
-R
1
OH
OH
OH
OCH 3
OH
OH
OH
OH
OH
OH
sec-butyl isopropyl sec-butyl sec-butyl sec-butyl sec-butyl sec-butyl sec-butyl sec-butyl se-c-butyl i-C H NHC i-C 3H 7NHCO i 3 H7 N C 2H C 2H phenyl-NHCO all yl -NH CO propargyl -NHCO 4 -chlorophenyl-NHCO 3, 4-dichlorophenyl-NHCO benzyl-NHCO C. i
C
4 4 EXAMPLE 28 13-Deoxv-23- rO-acetvl) oximnel -C–076-B2a-acrlycone In 1 ML of CH 2 C1 2 50 mg of 13-deoxy-23-oxime- C-076-B2a aglycone is stirred at 0 0 C with 6 pL of triethylamine and 1.25 equivalents of acetic anhydride for 24 hours. The mixture is evaporated to dryness, and the residue is dissolved in 10 mL of CH 2 Cl 2′ The CH 2 C1 2 solution is washed with H 2 0, dried over M 9 o 4 and evaporated to dryness to afford the title compound that is identified by mass spectrometry and NMR spectroscopy.
EXAMPLES 29-3 3 By the procedure of Example 28, the following 13-deoxy-23-C0-(substituted)oxime)C-076-B2a aglycones are prepared using the appropriate acid anhydride.
1,: i -21- 1 0 St
C
4t 4
YDR
4 P3 1 CH 3 3 II 2 rr t Y1 t 4 4 44*4*9 4
R-
1 R2
R
4 OH sec-butyl CICH 2
CO
OCH
3 sec-butyl CICH 2
CO
OH sec-butyl CH3OCH2CO OH sec-butyl CH 3
OCH
2
CO
OH isopropyl CH 3
OCH
2
CO
OH sec-butyl C6H5CH2CO EXAMPLE 34 13-Deoxy-23-semicarbazone-C-076-B2a aqlycone In 5 mL of dioxane, 60 mg of 13-deoxy-23-oxo- C-076-B2a-aglycone is stirred with 56.4 mg of NaOAc, 77 mg of semicarbazide hydrochloride and 18 L of HOAc, 25 for 6 days at room temperature. The mixture is poured on ice, mixed with 100-mL eachof H20 and CH2Cl 2 The CH 2 Cl 2 layer is separated. The aqueous is extracted with
CH
2 C1 2 and the combined CH 2 C1 2 solutions are washed with and evaporated to dryness. The residue is dissolved in 100 mL of Et20 and the solution is washed with 8 x 50 mL of water, dried (Na 2
SO
4 and evaporated to dryness to afford the title compoud.
EXAMPLES 35-41 Using the procedure of Example 34, the following semicarbazones and thiosemicarbazones are prepared: -22- 6L6R 3 H 3 IF Ot 3 T 4 484 ecbtl 3 sec-butyl 0 H H go 0OH sec-butyl S H H- 6tsOH isopropyl 0 H H *’OH sec-buty. 0 H H *”OH sec-butyl 0 H r3CH OH iso pr 1 0 H 0 3-Deoxv-23-(2-carbomethoxyhvdrazone)-C-076-B2a-aolvcone 15 *mL. -of MeOH, 50 mg of 13-deoxy-23-oxo- C-076-B2a-aglycoie is treated with 25 mg of methyl carbazate arid 10 P.L of HOAc. After 3 days, the mixture is poured on ice and diluted with H 0. The aqueous phase is saturated with NaCi and extracted with CH 2 C 2* The CH C1 extracts are dried (Na so) and evaporated to4 2 224 dryness. The residue is purified by chromatography on silica gel using 2% isopropanol in CH 2 C1 2 to afford the title compound.
Similarly, the 2 -carbethoxyhydra zone, 2-carbopropoxy and 2-carbobutoxy hydrazones are prepared using the corresponding carbazates.

Claims (16)

1. The compounds characterized by structural formula CH /0\ 0 2 33 T~ *0 900 Ac CH (I) wherein R1 is methoxy or hydroxy; R 2 is isopropyl or 4 t sec-butyl; X is oxygen, NOR 4 or N-NHR 5 R 4 is hydrogen, C 1 -C 6 alkyl, cl-C 4 alkoxymethyl, benzoyl, allyl, pro- pargyl, phenyl, CH 2 COO-alkyl (C 1 -C 4 N-(C 1 -C 6 alkyl)- carbamoyl, N-(allyl)carbamoyl, N-(propargyl)carbamoyl, N-(phenyl)carbamoyl, N-(chlorophenyl)carbamoyl, N-(di- chlorophenyl)carbamoyl, N-(benzyl)carbamoyl, 01- 6 b 00 alkanoyl, chloroacetyl, methoxyacetyl, phenylacetyl, optionally subsfituted on the phenyl ring with one or two halogens, C 1 -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups, phenoxyacetyl, optionally substituted on the phenyl ring by one or two halogens, C 1 -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups, or benzoyl, optionally substituted with one or two halogens, C 1 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups; R 5 is -NR6 7 C-NR 6 R 7 C-OR CCNR 6 R 7 C 1 -C 6 alkanoyl, formyl, C 1 -C 6 alkyl, i-NR 6 R 7 benzoyl, optionally sub- ii -24- stituted with one or two halogens, C 1 -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups; R 6 and R 7 are hydrogen or C 1 -C 6 alkyl; or phenyl, optionally substi- tuted with one or two halogens, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, or phenyl optionally substituted with one or two halogens, CI-C 4 alkyl groups,’ C 1 -C alkoxy groups or nitro groups, R 8 is C 1 -C 6 alkyl or phenyl optionally substituted with one or two halogens, C 1 -C 4 alkyl groups, C -C alkoxy groups or nitro groups; R is CI-C alkyl or phenyl optionally substituted with one or two halogens, l-C alkyl groups, C1-C4 alkoxy groups or nitro groups; and the pharmaceutically and pharmacologically acceptable salts thereof.

2. The compound according to Claim 1, wherein R 1 is hydroxy; R 2 is isopropyl or sec-butyl; X is oxygen, NOR 4 NNH- -NR6R7, or NNHCH 3 R 4 is C 1 -C 3 alkyl, N-(C -C 4 alkyl)carbimoyl, N-(phenyl)carbamoyl, N-(4-chlorophenyl)- carbamcyi, N-(allyl)carbamoyl, N-(benzyl)carbamoyl, C1-C 4 alkanoyl, chloroacetyl, methoxyacetyl, benzoyl and chlorobenzoyl and R 6 and R 7 are as described in said claim 1; and wherein R 1 is hydroxy; R 2 is isopropyl or sec-butyl; X is oxygen, NOR 4 NNH- -NRR7, NNH- -OR; and R 4 R 6 R 7 and ,-are as described in said claim 1.

3. The compound according to Claim 1, wherein R 1 is hydroxy; R 2 is sec-butyl; and X is NOCH 3 wherein R1 is hydroxy; R 2 is sec-butyl; and X is oxygen; and wherein R 1 is hydroxy; R 2 is sec-butyl; and X is NNH–NH 2

4. The method for the prevention, treatment or control of endoparasitic or ectoparasitic infections in j clim ad whrei R-is hdroy; isisoropi o I 1_ warm-blooded animals, said method characterized by: orally, topically or parenterally administering to an animal infected with endo- or ectoparasites, an endo- or -ectoparasiticidally effective amount of the compounds represented by structural formula P 2 cHc 3 S/CH (i) wherein R1 is methoxy or hydroxy; R 2 is isopropyl or sec-butyl; X is oxygen, NOR 4 or N-NHR 5 R 4 is hydrogen, C 1 -C 6 alkyl, C 1 -C 4 alkoxymethyl, benzoyl, allyl, pro- pargyl, phenyl, CH 2 COO-alkyl (C 1 -C 4 N-(C 1 -C 6 alkyl)- carbamoyl, N-(allyl)carbamoyl, N-(propargyl)carbamoyl, N-(phenyl)carbamoyl, N-(chlorophenyl)carbamoyl, N-(di- chlorophenyl)carbamoyl, N-(benzyl)carbamoyl, C1-C 6 alkanoyl, chloroacetyl, methoxyacetyl, phenylacetyl, optionally substituted on the phenyl ring with one or two halogens, C 1 -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups, phenoxyacetyl, optionally substituted on the phenyl ring by one or two halogens, C -C 4 alkyl groups, C 1 -C 4 alkoxy groups oa nitro groups, or benzoyl, optionally substituted with one or two halogens, C 1 -C 4 alkyl groups, C 4 alkoxy groups or nitro groups; R 5 is -NR 6 R 7 -NR 6 R 7 C-OR, NR 6 R C 1 -C 6 alkanoyl, formyl, C -C 6 alkyl, C-NR 6 R 7 benzoyl, optionally sub- 1 6 i7 -26- stituted with one or two halogens, C -C 4 alkyl groups, C -C 4 alkoxy groups or nitro groups; R 6 and R 7 are hydrogen or C 1 -C 6 alkyl; or phenyl, optionally substi- tuted with one or two halogens, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, or phenyl optionally substituted with one or two halogens, C 1 -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups, R 8 is C -C 6 alkyl or phenyl optionally substituted with one or two halogens, C 1 -C 4 alkyl groups, C-C 4 alkoxy groups or nitro groups; R 9 is C -C 6 alkyl or f phenyl optionally substituted with one or two halogens, S C -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups; and the pharmaceutically and pharmacologically acceptable salts thereof. A method according to Claim 4, wherein said compound is R 1 as hydroxy; R 2 is sec-butyl; and X is NOCH3; and wherein said compound is R 1 as hydroxy; R 2 is sec-butyl; and X is NNH-I-NH 2

6. A method for controlling plant insects topically or systemically, and protecting crops, trees, shrubs, stored grain and ornamentals, said method char- acterized by: applying an insecticidally-effctive amount of the compound represented by structural formula /C 3 C H 3 2 -27- C .C 0* CI I SC 491 C wherein R 1 is methoxy or hydroxy; R 2 is isopropyl or sec-butyl; X is oxygen, NOR 4 or N-NHR 5 R 4 is hydrogen, C 1 -C 6 alkyl, C 1 -C 4 alkoxymethyl, benzoyl, ally], pro- pargyl, phenyl, CH 2 COO-alkyl (C 1 -C 4 N-(C–C 6 alkyl)- carbamoyl, N-(allyl)carbamoyl, N-(propargyl)carbamoyl, N-(phenyl)carbamoyl, N-(chlorophenyl)carbamoyl, N-(di- chlorophenyl)carbamoyl, N-(benzyl)carbamoyl, C1-C 6 alkanoyl, chloroacetyl, methoxyacetyl, phenylacetyl, optionally substituted on the phenyl ring with one or two halogens, C 1 -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups, phenoxyacetyl, optionally substituted on the phenyl ring by one or two halogens, C 1 -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups, or benzoyl, optionally substituted with one or two halogens, C 1 -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups; R 5 is -NR6R7, -NR6R7, -OR8, NRR7 Rg Cl-C 6 alkanoyl, H 0 formyl, C 1 -C 6 alkyl, C-NR 6 R 7 benzoyl, optionally sub- stituted with one or two halogens, C 1 -C 4 alkyl groups, C1-C 4 alkoxy groups or nitro groups; R 6 and R 7 are hydrogen or C1-C6 alkyl; or phenyl, optionally substi- tuted with one or two halogens, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, or phenyl optionally substituted with one or two halogens, C 1 -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups, Rg.-is C1-C6 alkyl or phenyl optionally substituted with one or two halogens, C 1 -C 4 alkyl groups, C1-C4 alkoxy groups or nitro groups; R 9 is cl-C 6 alkyl or phenyl optionally substituted with one or two halogens, 1C-C4 alkyl groups, CI-C 4 alkoxy groups or nitro groups; and the pharmaceutically and pharmacologically acceptable salts thereof.

7. A method according to Claim 6, wherein said compound is R 1 as hydroxy; R 2 is sec-butyl; and X is NOCH 3 r I:~J I LC L 7^ -28- 44 9r 4 4. 4 4 $4 4 1A t I I,

8. A method for the control of plant nema- todes, said method characterized by: applying to the foilage of plants, the soil in which they are grown or into the trunks thereof, a nematicidally-effective amount of the compound represented by structural formula 1 3 ,i c~1′ \R 3 wherein R1 is methoxy or hydroxy; R 2 is isopropyl or sec-butyl; X is oxygen, NOR 4 or N-NHR 5 R 4 is hydrogen, C1-C 6 alkyl, C -C4 alkoxymethyl, benzoyl, allyl, pro- pargyl, phenyl, CH 2 COO-alkyl (C 1 -C 4 N-(C 1 -C 6 alkyl)- carbamoyl, N-(allyl)carbamoyl, N-(propargyl)carbamoyl, N-(phenyl)carbamoyl, N-(chlorophenyl)carbamoyl, N-(di- chlorophenyl)carbamoyl, N-(benzyl)carbamoyl, C1-C 6 alkanoyl, chloroacetyl, methoxyacetyl, phenylacetyl, optionally substituted on the phenyl ring with one or two halogens, C 1 -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups, phenoxyacetyl, optionally substituted on the phenyl ring by one or two halogens, C 1 -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups, or benzoyl, optionally substituted with one or two halogens, C 1 -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups; R 5 is Q S 0 00 0 I II II 1III II -NR 6 R 7 C-NR 6 R 7 C-OR 8 CCNR 6 R 7 R 9 C 1 -C 6 alkanoyl, H 0 formyl, C 1 -C 6 alkyl, C-NR R 7 benzoyl, optionally sub- tI ttf t14 4 4 4 4 Iberidi -Cu~ r r i i I r -29- stituted with one or two halogens, C 1 -C 4 alkyl groups, C1-C 4 alkoxy groups or nitro groups; R and R are hydrogen or C -C 6 alkyl; or phenyl, optionally substi- tuted with one or two halogens, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, or phenyl optionally substituted with one or two halogens, C 1 -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups, R 8 is C 1 -C 6 alkyl or phenyl optionally substituted with one or two halogens, C -C alkyl groups, C -C 4 alkoxy groups or nitro groups; R is C -C alkyl or 1 4 9 1 6 S phenyl optionally substituted with one or two halogens, C, -C4 alkyl groups, C -C 4 alkoxy groups or nitro groups; s and the pharmaceutically and pharmacologically acceptable salts thereof.

9. A method according to Claim 8, wherein said compound is R 1 as hydroxy; R 2 is sec-butyl; and X is NOCH 3 A composition for the treatment, prevention or control of endo- and/or ectoparasitic infections in warm-blooded animals, said composition characterized by: a prophylactically, therapeutically or pharmaceutically- effective amount of the compound represented by struc- tural formual S\ CH3 3″ I T (1) I r r4 30 wherein R 1 is methoxy or hydroxy; R 2 is isopropyl or sec-butyl; X is oxygen, NOR 4 or N-NHR 5 R 4 is hydrogen, C 1 -C 6 alkyl, C 1 -C 4 alkoxymethyl, benzoyl, allyl, propargyl, phenyl, CH 2 COO-alkyl (C 1 -C 4 N-(C 1 -C 6 alkyl)carbamoyl, N-(allyl)carbamoyl, N-(propargyl)carbamoyl, N-(phenyl)carbamoyl, N-(chlorophenyl)carbamoyl, N-(dichlorophenyl)carbamoyl, N-(benzyl)carbamoyl, C -C 6 alkanoyl, chloroacetyl, methoxyacetyl, phenylacetyl, optionally substituted on the phenyl ring with one or two halogens, C -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups, phenoxyacetyl, optionally substituted on the phenyl ring by one or two halogens, C 1 -C 4 alkyl groups, C1-C 4 alkoxy groups or nitro groups, or benzoyl, optionally substituted with one or two halogens, C 1 -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups; R 5 is -NR6R 7 C-NRR7, C-OR 8 CNRR 7 R C-C alkaloy, 1. formyl, C-C 6 alkyl, -NR6R 7 benzoyl, optionally substituted with one or two halogens, CI-C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups; R 6 and R 7 are hydrogen or C 1 -C 6 alkyl; or phenyl, optionally substituted with one or two halogens, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, or phenyl optionally substituted with one or two halogens, C 1 -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups, R 8 is C 1 -C 6 alkyl or phenyl optionally substituted with one or two halogens, C 1 -C 4 alkyl groups, C -C 4 alkoxy groups or nitro groups; R 9 is S C 1 -C 6 alkyl or phenyl optionally substituted with one or two halogens, S..a C 1 -C 4 alkyl groups, C1-C 4 alkoxy groups or nitro groups; and the pharmaceutically and pharmacologically acceptable salts theleof together S with a pharmaceutically acceptable carrier, diluent, adjuvant and/or exciplent.

11. A composition for controlling Insects, said composition characterized by: an insecticidally-effec- MRC/159x -31- f Ut U t ft .1 U ft tive amount of the compound represented by the structural formula 2 CH 3 wherein R 1 is methoxy or hydroxy; R 2 is isopropyl or sec-butyl; X is oxygen, NOR 4 or N-NHR.; R 4 is hydrogen, C 1 -C 6 alkyl, C 1 -C 4 alkoxymethyl, benzoyl, allyl, pro- parylpheylCH2 COakyl (C 1 -C 4 N-(C 1 -c 6 alkyl)- carbamoyl, N- (allyl) carbamoyl, N- (propargyl) carbamoyl, N- (phenyl) carbamoyl, N- (chiorophenyl) carbamoyl, N- (di- chiorophenyl)carbamoyl, N-(benzyl)carbamoyl, 1-6 alkanoyl, chioroacetyl, methoxyacetyl, phenylacetyl, optionally substituted on the phenyl ring with one or two halogens, C 1 -C 4 alkyl groups, C 1 -C 4 a lkoxy groups or nitro groups, pheno,,cyacetyl, optionally substituted on the phenyl ring by one or two halogens, C 1 -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups, or benzoyl, optionally substituted with one or two halogens, C 1 -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups; R 5 is 0 L !-NR 6 R 7 1 C-NR 6 R 7 1 L0R 8 UNR 6 R 7 ~R 9 C 1 -C 6 alkanoyl, formyl, C 1 -C 6 alkyl, C-NR 6 R 7 benzoyl, optionally sub- stituted with one or two halogens, C 1 -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups; R 6 and R 7are hydrogen or C 1 -C 6 alkyl; or phenyl, optionally substi- U IS ~U 41 4 lath,, 4 32 tuted with one or two halogens, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, or phenyl optionally substituted with one or two halogens, C -C 4 alkyl groups, C -C 4 alkoxy groups or nitro groups, R 8 is C 1 -C 6 alkyl or phenyl optionally substituted with one or two halogens, C -C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups; R 9 is C 1 -C 6 alkyl or phenyl optionally substituted with one or two halogens, Ci-C 4 alkyl groups, C 1 -C 4 alkoxy groups or nitro groups; and the pharmaceutically and pharmacologically acceptable salts thereof; and an inert carrier.

12. A 13-deoxy-23-oxo(keto) or a 23-imino derivative of a 13-deoxy C-076-aglycone compound as defined in claim 1 and as hereinbefore described with reference to any one of the examples.

13. A process for making a 13-deoxy-23-oxo(keto) or a 23-imino derivative of a 13-deoxy C-076-aglycone compound as defined in claim 1, substantially as herein described with reference to any one of the Examples.

14. A composition for the control of endoparasitic or ectoparasitic infections in warm-blooded animals, comprising a compound of claim 12 and an acceptable carrier, diluent, excipient and/or adjuvant.

15. A composition for the control of plant insects topically or systemically, and protecting crops, trees, shrubs, stored grain and/or ornamentals, comprising a compound of claim 12 and an insecticidally acceptable carrier, diluent, excipient and/or adjuvant.

16. A method for the prevention, treatment or control of endoparasitic or ectoparasitic Infections in a warm-blooded animal, comprising orally topically or parenterally administering to said animal an effective amount of a compound as defined In claim 12 and/or a composition as defined in claim 14.

17. A method for controlling plant insects topically or systemically, and protecting crops, trees, shrubs, stored grain and/or ornamentals, said method comprising applying an insecticidally effective amount of a compound of claim 12 and/or a composition of claim 15 to said crops, trees, shrubs, stored grain and/or ornamentals or to the locus thereof. MRC/159x 33

18. A method for controlling plant nematodes, comprising applying to the foliage of plants, the soil in which they are grown or into the trunks thereof, a nematicidally-effective amount of a compound of claim 12. DATED this TWENTIETH day of NOVEMBER 1989 American Cyanamid Company Patent Attorneys for the Applicant SPRUSON FERGUSON 4 4 1 4-.4 4 I Ic C 4 MRC/159X

AU78278/87A
1986-09-12
1987-09-11
Spiro derivatives

Ceased

AU593383B2
(en)

Applications Claiming Priority (2)

Application Number
Priority Date
Filing Date
Title

US90725986A

1986-09-12
1986-09-12

US907259

1986-09-12

Publications (2)

Publication Number
Publication Date

AU7827887A

AU7827887A
(en)

1988-03-17

AU593383B2
true

AU593383B2
(en)

1990-02-08

Family
ID=25423780
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU78278/87A
Ceased

AU593383B2
(en)

1986-09-12
1987-09-11
Spiro derivatives

Country Status (9)

Country
Link

EP
(1)

EP0260537A1
(en)

JP
(1)

JPS63115883A
(en)

KR
(1)

KR880003952A
(en)

AU
(1)

AU593383B2
(en)

CA
(1)

CA1301750C
(en)

IE
(1)

IE872440L
(en)

IL
(1)

IL83798A
(en)

NZ
(1)

NZ221715A
(en)

ZA
(1)

ZA876835B
(en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

GB8721377D0
(en)

1987-09-11
1987-10-21
Glaxo Group Ltd
Chemical compounds

NZ233680A
(en)

1989-05-17
1995-02-24
Beecham Group Plc
Avermectins and milbemycins and compositions thereof

GB9024926D0
(en)

1990-11-16
1991-01-02
Beecham Group Plc
Novel treatment

GB9024927D0
(en)

1990-11-16
1991-01-02
Beecham Group Plc
Novel treatment

DE102010064245A1
(en)

2010-12-28
2012-06-28
Bayer Animal Health Gmbh
Use of macrocyclic lactones used in controlling endoparasitic filariae and gastrointestinal nematodes, particularly used in controlling heartworm

WO2012028556A1
(en)

2010-08-31
2012-03-08
Bayer Animal Health Gmbh
Macrocyclic lactones and their use and their combinations with other active substances

CN103396464B
(en)

2013-07-16
2017-04-05
河北威远动物药业有限公司
A kind of preparation method of ivermectin

Citations (3)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU6056986A
(en)

1985-07-27
1987-05-14

Pfizer Corp.

25-avermectin derivatives

AU6991187A
(en)

1986-03-12
1987-09-17

American Cyanamid Company

Macrolide compounds

AU7387387A
(en)

1986-06-06
1987-12-10

Wyeth Holdings Corporation

Macrolide compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

PH16612A
(en)

1977-12-19
1983-11-28
Merck & Co Inc
13-halo and 13-deoxy derivatives of c-076 compounds

US4289760A
(en)

1980-05-02
1981-09-15
Merck & Co., Inc.
23-Keto derivatives of C-076 compounds

US4469682A
(en)

1983-01-28
1984-09-04
Merck & Co., Inc.
Avermectin and milbemycin phosphate esters, pharmaceutical compositions, and method of use

ES8802229A1
(en)

1985-04-30
1988-04-16
Glaxo Group Ltd
Macrolide antibiotics and their preparation

1987

1987-09-03
EP
EP87112859A
patent/EP0260537A1/en
not_active
Ceased

1987-09-06
IL
IL83798A
patent/IL83798A/en
not_active
IP Right Cessation

1987-09-08
NZ
NZ221715A
patent/NZ221715A/en
unknown

1987-09-10
CA
CA000546552A
patent/CA1301750C/en
not_active
Expired – Fee Related

1987-09-11
IE
IE872440A
patent/IE872440L/en
unknown

1987-09-11
AU
AU78278/87A
patent/AU593383B2/en
not_active
Ceased

1987-09-11
KR
KR870010146A
patent/KR880003952A/en
not_active
Application Discontinuation

1987-09-11
ZA
ZA876835A
patent/ZA876835B/en
unknown

1987-09-12
JP
JP62229439A
patent/JPS63115883A/en
active
Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU6056986A
(en)

1985-07-27
1987-05-14
Pfizer Corp.
25-avermectin derivatives

AU6991187A
(en)

1986-03-12
1987-09-17
American Cyanamid Company
Macrolide compounds

AU7387387A
(en)

1986-06-06
1987-12-10
Wyeth Holdings Corporation
Macrolide compounds

Also Published As

Publication number
Publication date

ZA876835B
(en)

1988-03-15

IL83798A
(en)

1991-08-16

CA1301750C
(en)

1992-05-26

IE872440L
(en)

1988-03-12

KR880003952A
(en)

1988-05-31

EP0260537A1
(en)

1988-03-23

JPS63115883A
(en)

1988-05-20

NZ221715A
(en)

1990-10-26

AU7827887A
(en)

1988-03-17

Contact information